Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Sensyne Health plc, the British clinical AI technology company, announces that its Annual Report and Accounts for the year ended 30 April 2019 is now available on the Group’s website at www.sensynehealth.com/investors.
Sensyne Health plc, the British Clinical AI technology company, announces its audited full year results for the 12 months ended 30 April 2019.
The Board of Directors of Promore Pharma AB has resolved to carry out a new share issue with preferential rights for the Company’s existing shareholders of a total of SEK 75 million excluding transaction costs.
New myTXTL bulk packagings align with volumes required for high-throughput organizations in synthetic biology.
For the past five years, there have been more than 400 mergers and acquisitions with companies in the gene therapy, immuno-oncology, microbiome and orphan drugs therapeutic space in North America and that trend is likely to continue, according to a new analysis.
Less than one month after filing for bankruptcy, beleaguered Bay Area microbiome company uBiome is now shutting its doors and selling off assets.
GENFIT, a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases, announces its first half 2019 financial results.
Estimated total sales of HEMOBLAST™ Bellows for the first nine months of 2019 are expected to show strong growth at €2.5 million (compared to €1.5 million for the first half of 2019 and €0.6 million for the full year 2018) and are expected to be on track to achieve the 2019 revenue guidance range of €4.0-€4.5 million
Amryt, a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases, announces interim results for the six months ended 30 June 2019.
Motif Bio plc announced unaudited financial results for the half year ended June 30, 2019 and reported on its progress year to date.